We have 4 of 27 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Current mechanistic evidence supporting apremilast as a potential multitarget repurposing candidate in AD is synthesized, thereby addressing key knowledge gaps in the current literature.
This narrative review critically evaluates the available experimental evidence supporting the repurposing potential of Alogliptin for HD and identifies alogliptin as a potent repurposable agent and the necessity to conduct specific experimental and clinical research to determine its effectiveness.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
